Copy Link Print Information

Dabrafenib

(Synonyms: GSK2118436A; GSK2118436)
83 Cited Publications
Revisión del cliente

Based on 83 publication(s) in Google Scholar

Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.94%
  • No. CAS: 1195765-45-7
  • Fòrmula: C23H20F3N5O2S2
  • Peso molecular:519.56
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Dabrafenib Chemical Structure
    Dabrafenib Chemical Structure
  • Experimental Validation Results for Dabrafenib
  • Experimental Validation Results for Dabrafenib
  • Experimental Validation Results for Dabrafenib
  • Experimental Validation Results for Dabrafenib
  • Experimental Validation Results for Dabrafenib
  • Experimental Validation Results for Dabrafenib
No. CAS: 1195765-45-7
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Dabrafenib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Dabrafenib

More
Customer Validation & Images
WBIn Vivo Efficacy StudyCell Proliferation/Viability AssayIF
  • Cell Proliferation/Viability Assay
  • WB
  • In Vivo Efficacy Study
  • WB
  • IF
  • WB

Ver todos los productos específicos de isoformas Raf

More

Ver todos los productos específicos de isoformas CDK

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Dabrafenib Chemical Structure
    Dabrafenib Chemical Structure
    1/16
  • 1/16

    Dabrafenib purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Oct:146:157151. [Abstract]

    Customer Validation
     Dabrafenib (20 μM; 24-48 h). Cell viability is assessed using CCK-8 assays. Dabrafenib (Dab) is used to treat BRAFi-resistant melanoma cells [WM164-DR] for 24 or 48 hours.

  • 1/16

    Dabrafenib purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun 3:e2400023. [Abstract]

    Customer Validation
     Inhibitory effects of Dabrafenib (40 µM; 24 h) on TRIM24 phosphorylation and protein interaction between TRIM24 and the DNA-PK complex in NHA/HRasV12/TRIM24 cells. Cells were treated with Dabrafenib for 24 h.

  • 1/16

    Dabrafenib purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Mar 19;5(3):101471. [Abstract]

    Customer Validation
     Dabrafenib (30 mg/kg, p.o., 28 days). Relative tumor volumes and mice weights in sequential treatment groups with either vehicle or NEO2734 in A375 subcutaneous-bearing mice. Mice were switched to vehicle or NEO2734 treatment at day 28 (n = 6 for dabrafenib + trametinib to vehicle, n = 5 for dabrafenib + trametinib to NEO2734) (4 mg/kg NEO2734, 5 days/week; 30 mg/kg dabrafenib + 0.6 mg/kg trametinib daily).

  • 1/16

    Dabrafenib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Mar 16;37(3):387-402.e7. [Abstract]

    Customer Validation
     MCF-7 cells were seeded in 10-11 M E2 to which fulvestrant (F), dabrafenib (D), trametinib (T) or selumetinib (S) were subsequently added at 10-9, 10-6, 10-7 or 10-6 M, respectively. After 6 days, proteins were measured by immunoblotting, and phosphorylation levels (as defined by the levels of the phosphorylated form over total protein) relative to the vehicle-treated cells were set to 1.

  • 1/16

    Dabrafenib purchased from MedChemExpress. Usage Cited in: Cell Syst. 2020 Nov 18;11(5):478-494.e9. [Abstract]

    Customer Validation
     Dabrafenib (25 mg/kg; p.o.; 5 days). Immunofluorescence microscopy of pERK in A375 mouse xenografts treated either with vehicle alone or dabrafenib plus trametinib for 5 days.

  • 1/16

    Dabrafenib purchased from MedChemExpress. Usage Cited in: Int J Cancer. 2019 Mar 15;144(6):1379-1390. [Abstract]

    Customer Validation
     Western blot confirmed increased MAPK pathway activity in NEC-DUE2 cells when compared to NECDUE1. Treatment with PLX4032 (1 μM), Dabrafenib (100 nM), or GSK1120212 (100 nM) for 4 hours leads to decreased MAPK signaling in NEC-DUE2 cells. Lysates are immunoblotted for the proteins indicated.

  • Dabrafenib